Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by Eqis Capital Management Inc.

Eqis Capital Management Inc. increased its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 0.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,776 shares of the biopharmaceutical company’s stock after buying an additional 38 shares during the period. Eqis Capital Management Inc.’s holdings in Alexion Pharmaceuticals were worth $824,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in ALXN. Guardian Life Insurance Co. of America increased its position in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares during the period. Meeder Asset Management Inc. bought a new position in Alexion Pharmaceuticals during the first quarter valued at approximately $111,000. Independent Portfolio Consultants Inc. increased its position in Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 340 shares during the period. FUKOKU MUTUAL LIFE INSURANCE Co increased its position in Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 100 shares during the period. Finally, Princeton Alpha Management LP bought a new position in Alexion Pharmaceuticals during the first quarter valued at approximately $219,000. 94.75% of the stock is currently owned by hedge funds and other institutional investors.

Alexion Pharmaceuticals, Inc. (ALXN) opened at 125.78 on Tuesday. The stock’s 50 day moving average is $112.16 and its 200 day moving average is $122.31. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $145.41. The firm has a market cap of $28.24 billion, a P/E ratio of 59.92 and a beta of 1.38.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.33. The business had revenue of $870 million during the quarter, compared to analysts’ expectations of $826.63 million. Alexion Pharmaceuticals had a return on equity of 11.72% and a net margin of 14.52%. The business’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.11 EPS. On average, equities research analysts expect that Alexion Pharmaceuticals, Inc. will post $5.32 EPS for the current year.

WARNING: This article was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://sportsperspectives.com/2017/07/18/alexion-pharmaceuticals-inc-alxn-shares-bought-by-eqis-capital-management-inc.html.

Several equities research analysts recently weighed in on the stock. UBS AG restated a “buy” rating and issued a $140.00 price target (down previously from $143.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 31st. BMO Capital Markets restated an “outperform” rating and issued a $158.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, May 1st. SunTrust Banks, Inc. restated a “buy” rating and issued a $165.00 price target on shares of Alexion Pharmaceuticals in a research report on Friday. Leerink Swann restated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Finally, Stifel Nicolaus restated a “buy” rating and issued a $157.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Eight investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $156.62.

In other Alexion Pharmaceuticals news, Director Bros. Advisors Lp Baker bought 1,348,955 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The stock was purchased at an average price of $116.32 per share, for a total transaction of $156,910,445.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ludwig Hantson bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The shares were acquired at an average price of $116.72 per share, with a total value of $1,167,200.00. Following the purchase, the chief executive officer now owns 38,725 shares of the company’s stock, valued at $4,519,982. The disclosure for this purchase can be found here. Insiders bought a total of 2,019,734 shares of company stock valued at $235,606,846 in the last quarter. Company insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply